Chronic Lymphocytic Leukemia (CLL)

CLL is a slow-growing blood cancer that affects B lymphocytes and is most common in older adults. It often leads to immune dysfunction.

HSCT may be considered for younger, high-risk patients who do not respond to targeted therapies.

While many patients benefit from novel agents, HSCT remains the only curative option for some.